PURPOSE: To compare the diagnostic accuracy of the Matrix frequency-doubling technology (FDT) 24-2, first-generation FDT N-30 (FDT N-30), and standard automated perimetry (SAP) tests of visual function. METHODS: One eye of each of 85 glaucoma patients and 81 healthy controls from the Diagnostic Innovations in Glaucoma Study was included. Evidence of glaucomatous optic neuropathy on stereophotographs was used to classify the eyes. Matrix FDT 24-2, first-generation FDT N-30, and SAP-SITA 24-2 tests were performed on all participants within 3 months. Receiver operating characteristic (ROC) curves were generated and used to determine sensitivity levels at 80% and 90% specificity for mean deviation (MD), pattern standard deviation (PSD), number of total deviation (TD), and pattern deviation (PD) points triggered at less than 5% and 1%. The tests were compared using the best parameter for each test (that with the highest area under the ROC curve) and with the PSD. RESULTS: The best parameters were MD for SAP (0.680), PSD for FDT N-30 (0.733), and number of TD less than 5% points for FDT 24-2 (0.774). Using the best parameter, the area under the ROC curve was significantly larger for FDT 24-2 than for SAP (P = 0.01). No statistically significant differences were observed between SAP and FDT N-30 (P = 0.21) and FDT N-30 and FDT 24-2 (P = 0.26). Similar results were obtained when the PSD was used to compare the tests, with the exception that the area under the ROC curve for the FDT N-30 test (0.733) was significantly larger than that of the SAP-SITA (0.641; P = 0.03). CONCLUSIONS: The performance of the Matrix FDT 24-2 was similar to that of the first-generation FDT N-30. The Matrix FDT 24-2 test was consistently better than SAP at discriminating between healthy and glaucomatous eyes. Further studies are needed to evaluate the ability of the Matrix FDT 24-2 to monitor glaucoma progression.
PURPOSE: To compare the diagnostic accuracy of the Matrix frequency-doubling technology (FDT) 24-2, first-generation FDT N-30 (FDT N-30), and standard automated perimetry (SAP) tests of visual function. METHODS: One eye of each of 85 glaucomapatients and 81 healthy controls from the Diagnostic Innovations in Glaucoma Study was included. Evidence of glaucomatous optic neuropathy on stereophotographs was used to classify the eyes. Matrix FDT 24-2, first-generation FDT N-30, and SAP-SITA 24-2 tests were performed on all participants within 3 months. Receiver operating characteristic (ROC) curves were generated and used to determine sensitivity levels at 80% and 90% specificity for mean deviation (MD), pattern standard deviation (PSD), number of total deviation (TD), and pattern deviation (PD) points triggered at less than 5% and 1%. The tests were compared using the best parameter for each test (that with the highest area under the ROC curve) and with the PSD. RESULTS: The best parameters were MD for SAP (0.680), PSD for FDT N-30 (0.733), and number of TD less than 5% points for FDT 24-2 (0.774). Using the best parameter, the area under the ROC curve was significantly larger for FDT 24-2 than for SAP (P = 0.01). No statistically significant differences were observed between SAP and FDT N-30 (P = 0.21) and FDT N-30 and FDT 24-2 (P = 0.26). Similar results were obtained when the PSD was used to compare the tests, with the exception that the area under the ROC curve for the FDT N-30 test (0.733) was significantly larger than that of the SAP-SITA (0.641; P = 0.03). CONCLUSIONS: The performance of the Matrix FDT 24-2 was similar to that of the first-generation FDT N-30. The Matrix FDT 24-2 test was consistently better than SAP at discriminating between healthy and glaucomatous eyes. Further studies are needed to evaluate the ability of the Matrix FDT 24-2 to monitor glaucoma progression.
Authors: Felipe A Medeiros; Linda M Zangwill; Christopher Bowd; Pamela A Sample; Robert N Weinreb Journal: Am J Ophthalmol Date: 2005-06 Impact factor: 5.258
Authors: Paul H Artes; Donna M Hutchison; Marcelo T Nicolela; Raymond P LeBlanc; Balwantray C Chauhan Journal: Invest Ophthalmol Vis Sci Date: 2005-07 Impact factor: 4.799
Authors: Lyne Racette; Jeffrey M Liebmann; Christopher A Girkin; Linda M Zangwill; Sonia Jain; Lida M Becerra; Felipe A Medeiros; Christopher Bowd; Robert N Weinreb; Catherine Boden; Pamela A Sample Journal: Arch Ophthalmol Date: 2010-05
Authors: Ali Tafreshi; Lyne Racette; Robert N Weinreb; Pamela A Sample; Linda M Zangwill; Felipe A Medeiros; Christopher Bowd Journal: Am J Ophthalmol Date: 2010-03 Impact factor: 5.258
Authors: Robert O Duncan; Pamela A Sample; Christopher Bowd; Robert N Weinreb; Linda M Zangwill Journal: Vision Res Date: 2012-03-29 Impact factor: 1.886
Authors: Ali Tafreshi; Pamela A Sample; Jeffrey M Liebmann; Christopher A Girkin; Linda M Zangwill; Robert N Weinreb; Maziar Lalezary; Lyne Racette Journal: Invest Ophthalmol Vis Sci Date: 2008-10-31 Impact factor: 4.799
Authors: Folkert K Horn; Vicki Scharch; Christian Y Mardin; Robert Lämmer; Jan Kremers Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-02-17 Impact factor: 3.117